EOLS
Price
$5.99
Change
+$0.01 (+0.17%)
Updated
Sep 26 closing price
Capitalization
387.47M
43 days until earnings call
OMID
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Sep 26 closing price
Capitalization
1.83M
15 days until earnings call
Interact to see
Advertisement

EOLS vs OMID

Header iconEOLS vs OMID Comparison
Open Charts EOLS vs OMIDBanner chart's image
Evolus
Price$5.99
Change+$0.01 (+0.17%)
Volume$1.28M
Capitalization387.47M
Omid
Price$0.02
Change-$0.00 (-0.00%)
Volume$110.2K
Capitalization1.83M
EOLS vs OMID Comparison Chart in %
Loading...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EOLS vs. OMID commentary
Sep 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EOLS is a Buy and OMID is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 29, 2025
Stock price -- (EOLS: $5.99 vs. OMID: $0.02)
Brand notoriety: EOLS and OMID are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EOLS: 83% vs. OMID: 405%
Market capitalization -- EOLS: $387.47M vs. OMID: $1.83M
EOLS [@Pharmaceuticals: Generic] is valued at $387.47M. OMID’s [@Pharmaceuticals: Generic] market capitalization is $1.83M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EOLS’s FA Score shows that 0 FA rating(s) are green whileOMID’s FA Score has 1 green FA rating(s).

  • EOLS’s FA Score: 0 green, 5 red.
  • OMID’s FA Score: 1 green, 4 red.
According to our system of comparison, OMID is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EOLS’s TA Score shows that 4 TA indicator(s) are bullish while OMID’s TA Score has 2 bullish TA indicator(s).

  • EOLS’s TA Score: 4 bullish, 4 bearish.
  • OMID’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than OMID.

Price Growth

EOLS (@Pharmaceuticals: Generic) experienced а -4.77% price change this week, while OMID (@Pharmaceuticals: Generic) price change was +3.49% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.16%. For the same industry, the average monthly price growth was +24.25%, and the average quarterly price growth was +66.99%.

Reported Earning Dates

EOLS is expected to report earnings on Nov 11, 2025.

OMID is expected to report earnings on Oct 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EOLS($387M) has a higher market cap than OMID($1.83M). OMID YTD gains are higher at: -3.797 vs. EOLS (-45.743).
EOLSOMIDEOLS / OMID
Capitalization387M1.83M21,136%
EBITDA-33.58MN/A-
Gain YTD-45.743-3.7971,205%
P/E RatioN/AN/A-
Revenue278MN/A-
Total Cash61.7MN/A-
Total Debt155MN/A-
FUNDAMENTALS RATINGS
EOLS vs OMID: Fundamental Ratings
EOLS
OMID
OUTLOOK RATING
1..100
5150
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
8397
SMR RATING
1..100
1001
PRICE GROWTH RATING
1..100
9563
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OMID's Valuation (79) in the null industry is in the same range as EOLS (92) in the Pharmaceuticals Major industry. This means that OMID’s stock grew similarly to EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (83) in the Pharmaceuticals Major industry is in the same range as OMID (97) in the null industry. This means that EOLS’s stock grew similarly to OMID’s over the last 12 months.

OMID's SMR Rating (1) in the null industry is significantly better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that OMID’s stock grew significantly faster than EOLS’s over the last 12 months.

OMID's Price Growth Rating (63) in the null industry is in the same range as EOLS (95) in the Pharmaceuticals Major industry. This means that OMID’s stock grew similarly to EOLS’s over the last 12 months.

OMID's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for EOLS (100) in the Pharmaceuticals Major industry. This means that OMID’s stock grew somewhat faster than EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EOLSOMID
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 24 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
81%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
75%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
75%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TIMCF1.060.09
+9.46%
Titan Mining Corporation
CMWAY108.350.99
+0.92%
Commonwealth Bank of Australia
PHMMF99.90N/A
N/A
Pharma Mar SA
WRFRF2.82-0.06
-2.09%
Wharf Real Estate Investment Co Ltd.
LMSQF0.14N/A
-3.41%
Latin Metals Inc.

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
+0.17%
PRGO - EOLS
44%
Loosely correlated
+3.32%
AMRX - EOLS
33%
Poorly correlated
+1.56%
LNTH - EOLS
32%
Poorly correlated
-1.67%
ALKS - EOLS
30%
Poorly correlated
+2.80%
NBIX - EOLS
29%
Poorly correlated
+0.79%
More

OMID and

Correlation & Price change

A.I.dvisor tells us that OMID and EOLS have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OMID and EOLS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMID
1D Price
Change %
OMID100%
+2.15%
EOLS - OMID
22%
Poorly correlated
+0.17%
OILFF - OMID
8%
Poorly correlated
N/A
PHCUF - OMID
5%
Poorly correlated
N/A
ROMJF - OMID
2%
Poorly correlated
+0.12%
OASMY - OMID
2%
Poorly correlated
N/A
More